Back
#1
37.4%
Top 61%
8.9%
Top 2%
7.4%
Top 0.5%
5.8%
Top 2%
5.8%
Top 9%
4.8%
Top 0.5%
4.4%
Top 61%
4.4%
Top 34%
2.2%
Top 1%
2.2%
Top 61%
1.1%
Top 21%
1.1%
Top 5%
0.8%
Top 7%
0.8%
Top 3%
0.5%
Top 27%
0.5%
Top 2%
0.5%
Top 19%
0.5%
Top 3%
0.5%
Top 10%
0.5%
Top 16%
0.5%
Top 16%
0.5%
Top 9%
0.5%
Bevacizumab in ovarian cancer: time-dependent changes in risk of progression
2023-02-17
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundBevacizumab has been used in the first-line and recurrent treatment of ovarian cancer. However, the time-dependent changes in the effects of bevacizumab administration are not fully understood. MethodsThe ICON7-A cohort was generated from two ancillary analyses of the ICON7 trial. ICON7-A tumors were classified as homologous recombination deficient (HRD) or non-HRD based on their gene expression profiles. Kaplan-Meier curves from published phase III trials were graphically analyzed to...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
Frontiers in Oncology
34 training papers
4
British Journal of Cancer
22 training papers
5
Clinical Cancer Research
22 training papers
6
eLife
262 training papers
7
Cancer Medicine
17 training papers
8
Scientific Reports
701 training papers
9
Nature Communications
483 training papers
10
BMC Cancer
21 training papers
11
BMJ Open
553 training papers
12
JAMA Network Open
125 training papers
13
Diagnostics
36 training papers
14
PeerJ
46 training papers
15
Aging
18 training papers
16
Journal of Clinical Medicine
77 training papers
17
International Journal of Cancer
18 training papers
18
Heliyon
57 training papers
19
Cell Reports
25 training papers
20
Communications Medicine
63 training papers
21
Frontiers in Immunology
140 training papers
22
iScience
74 training papers
23
International Journal of Molecular Sciences
39 training papers